Evaluating single cell mutations in lung cancer samples
Prospective Evaluation of Single Cell Mutations in a Panel of Known Oncogenes in NSCLC Surgical Specimens (TAP-NSCLC)
This study is testing a new method to look at tiny genetic changes in lung cancer cells from patients to see how these changes might affect treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Milano Bicocca Academic / other |
| Locations | 1 site (Monza, MB) |
| Trial ID | NCT06050278 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the feasibility of using the Tapestri method to analyze single cell mutations in known oncogenes from surgical specimens of patients with non-small cell lung cancer (NSCLC). The study will focus on understanding the genetic heterogeneity of NSCLC by examining tissue samples from patients at stages I to III. By tracing the clonal architecture and mutation timelines, the research seeks to prioritize molecular targets and identify evolutionary patterns that could influence treatment outcomes. The study will include a limited number of patients, and results will be shared through narrative reports rather than statistical analyses.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a histologically confirmed diagnosis of operable NSCLC.
Not a fit: Patients under 18 years old or those with unconfirmed NSCLC diagnoses will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance personalized treatment strategies for NSCLC patients by identifying key genetic alterations and their implications for therapy response.
How similar studies have performed: While the approach of analyzing single cell mutations is gaining traction, this specific application using the Tapestri method in NSCLC is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 18 years old. * histological diagnosis of NSCLC technically operable following multidisciplinary discussion * informed consent freely granted and obtained before the start of the study Exclusion Criteria: * age under 18 years old * unconfirmed NSCLC histological diagnosis * medical treatment with neoadjuvant purposes * absence of informed consent
Where this trial is running
Monza, MB
- Fondazione IRCCS San Gerardo dei Tintori — Monza, Mb, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.